<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873442</url>
  </required_header>
  <id_info>
    <org_study_id>NBWYKY2016-06-005</org_study_id>
    <nct_id>NCT02873442</nct_id>
  </id_info>
  <brief_title>Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer</brief_title>
  <official_title>Clinical Study Using Precision Cell Immunotherapy Combination With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ningbo Cancer Hospital</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ningbo Cancer Hospital</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of cell therapy using precision cells Combined With
      TACE in Advanced Liver Cancer.

      Eligibility:

      Individuals greater than or equal to 18 years of age and less than or equal to 65 years of
      age who have been diagnosed with Advanced Liver Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 40 patients may be enrolled over a period of 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Questionnaire will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Precision Cell Immunotherapy</condition>
  <condition>Transcatheter Arterial Chemoembolization</condition>
  <condition>Advanced Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Precision cells combined with TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Arterial Chemoembolization:
patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive MMC,EADM hepatic arterial infusion,6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.</description>
    <arm_group_label>Precision cells combined with TACE</arm_group_label>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Precision Cells</intervention_name>
    <description>DC cell suspension (1×107 DC+ physiological saline
+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.</description>
    <arm_group_label>Precision cells combined with TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18~65 years old, male or female;

          2. Life expectancy≥6 months;

          3. ECOG score: 0-3;

          4. Advanced Malignancies (lung cancer, gastric cancer) were diagnosed by pathological or
             clinical physicians,and Diagnosis of hepatocellular carcinoma (HCC), surgery can not
             be performed but TACE treatment can be carried out;

          5. Enough venous channel, no other contraindications to the separation and collection of
             white blood cells;

          6. Laboratory examination: white blood cell≥3 x 10*9/L, blood platelet count≥60 x 10*/L,
             hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less
             than five times of the normal level; serum creatinine less than 1.5 times of the
             normal level；

          7. Signed informed consent；

          8. Women of child-bearing age must have evidence of negative pregnancy test and be
             willing to practice birth control after 2 weeks following the cells transfusion.

        Exclusion Criteria:

          1. Expected Overall survival ＜ 3 months

          2. The tumor size or quantity is not suitable for interventional treatment or portal vein
             tumor thrombus

          3. Liver function is Childs Pugh C

          4. Had received TACE therapy previously or in radiotherapy at present,or taking Sola
             Feeney

          5. Other serious diseases:the heart,lung, kidney,digestive, nervous, mental disorders,
             immune regulatory diseases, metabolic diseases, infectious diseases, etc.

          6. Unable or unwilling to provide informed consent, or fail to comply with the test
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huajun Jin</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Cell Therapy Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qijun Qian</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Cell Therapy Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiangtao Wang</last_name>
    <role>Study Director</role>
    <affiliation>Ningbo No.5 Hospital (Ningbo Cancer Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bi Wang</last_name>
    <phone>86-13310088259</phone>
    <email>biwang0218@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ningbo No.5 Hospital (Ningbo Cancer Hospital)</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bi Wan</last_name>
      <phone>86-13310088259</phone>
      <email>biwang0218@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiangtao Wang</last_name>
      <phone>86-15888102792</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Precision Cell Immunotherapy</keyword>
  <keyword>Transcatheter Arterial Chemoembolization</keyword>
  <keyword>Advanced Liver Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

